The MDACC group postulated that the outcome of TP53-mutated AML/MDS patients are not uniformly poor and focused on identify potential prognostic factors predicting survival in those patients who underwent ASCT after achieving a CR (65). Here, TP53 is linked to acute myeloid leukemia.